South Korea's Celltrion Healthcare Co. on Monday said it launched on the US market Vegzelma, a biosimilar of Bevacizumab, a medication for colorectal and breast cancer sold under the name Avastin.The company has prepared for the launch since September last year, when it received approval to se
Celltrion's Vegzelma Celltrion Healthcare Co. Ltd. said on Thursday that it launched Vegzelma, a biosimilar to the anti-cancer drug Avastin (active ingredient: bevacizumab) in Japan.In September last year, Vegzelma obtained marketing approval for metastatic colorectal cancer, non-small cell lun
Celltrion's Remsima South Korea's Celltrion Healthcare Co. on Tuesday said that for the second straight year, it landed an order for infliximab, an antibody used to treat autoimmune disease, in Brazil, the largest pharmaceutical market in Latin America.The company will supply in the first half
Celltrion's Remsima SC (Courtesy of Celltrion) Celltrion Healthcare Co., South Korean biopharmaceutical giant Celltrion Inc.’s global marketing affiliate, posted its record-high second-quarter revenue on Tuesday.The marketing affiliate achieved 519 billion won ($396 million) in revenue, 7